2024-02-13T00:00:00.000+11:00
Ongoing

102 Hummingbird

102 Hummingbird
Solid Tumors

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Trial overview

Topic

Solid tumors

Eligibility criteria

Inclusion criteria:

  • 18 Years and older
  • All genders 
  • 3 month life expectancy
  • Sterile and or not pregnant
  • Diagnosed with advanced metastatic pancreatic cancer and not recieved prior treatment with gemcitabine or nab-paclitaxe

Exclusion Criteria:

Prior treatment with HMBD-001, pertuzumab, or an agent that specifically targets HER3, including pan-HER tyrosine kinase inhibitors

Study details

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in 
participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 
mutations.

Further information

Please click here for more information

Location
Northshore :::

Brisbane – ICON Cancer Clinic South Brisbane

Brisbane – ICON Cancer Clinic South Brisbane :::

Malvern – Cabrini Health

Malvern – Cabrini Health :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.